Commentary: Tasting individual ingredients of meso soup: Can 'omics bring out the flavor?

Our plain-English summary of Commentary: Tasting individual ingredients of meso soup: Can 'omics bring out the flavor?, by H.I. Pass (The Journal of Thoracic and Cardiovascular Surgery, 2020).

The study

• Author: H.I. Pass
• Journal: The Journal of Thoracic and Cardiovascular Surgery
• Published: 2020;160(4):1084-1085
• Type of article: Editorial, Comment
• Read it: PubMed · Publisher

In plain English

This is a short commentary, not a research study, and it reported no new patient data. The author, from a thoracic surgery department in New York, responded to a review by Severson and colleagues on the genetic and molecular study ('omics') of pleural mesothelioma. The author described a tumor process called epithelial mesenchymal transition (EMT), which Severson and colleagues discussed, and noted that two independent laboratories using different genomic methods appeared to reach the same conclusion about it. According to the author, high EMT resembles the sarcomatoid tumor type and low EMT resembles the epithelial type. The author cautioned that molecular risk predictions may not be sensitive and specific enough to forecast an individual patient's outcome. Because mesothelioma is polyclonal, a single biopsy may not show the molecular makeup of other parts of the tumor. The author concluded that evolving molecular techniques are broadening understanding of mesothelioma. The commentary did not discuss asbestos or any other exposure.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Commentary (opinion piece) on another article; no new data
• Who was studied: No patients were studied. The commentary discussed a review by Severson and colleagues on molecular research in pleural mesothelioma.
• The authors' conclusion: The author concluded that evolving molecular biology techniques are broadening understanding of mesothelioma.
• Limitations the authors state:
  • The author cautioned that molecular prognostic tools (such as claudin and vimentin ratios and epithelial and sarcomatoid scores) may lack the sensitivity and specificity needed to predict outcome for an individual patient. This is a caution about the research field, not a limitation of a study.
  • The author noted that mesothelioma is polyclonal, so predictions based on a single biopsy may not reflect the molecular type of other areas of the tumor.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Related studies

• Ingredients such as trehalose and hesperidin taken as supplements or foods reverse alterations in human T cells, reducing asbestos exposure-induced antitumor immunity — S. Yamamoto, S. Lee, et al. (2021)
• South Africa asbestos ruling may bring flood of claims to London — Lloyd's of London (2000)
• Mesothelioma in the age of "Omics": Before and after The Cancer Genome Atlas — D.T. Severson, A. De Rienzo, et al. (2020)
• Conventional and novel "omics"-based approaches to the study of carbon nanotubes pulmonary toxicity — C. Ventura, A. Sousa-Uva, et al. (2018)
• Commentary: Not only SMART clinically, but translationally! — H.I. Pass (2020)
• Invited commentary — H.I. Pass (2012)

Browse more research in The Journal of Thoracic and Cardiovascular Surgery, or return to medical research.